United States Patent 9,617,546: Claim Scope, Exclusivity, and C5 Aptamer Patent Landscape

US Patent 9,617,546 protects a specific C5-binding aptamer identified as SEQ ID NO: 4, pharmaceutical compositions containing that aptamer, and therapeutic use against complement C5, C5a, and C5b-9-mediated disorders. The patent is composition-of-matter and method-of-use protection, not a broad patent on every C5 inhibitor.

The claims are relevant to avacincaptad pegol, marketed as Izervay by Astellas subsidiary Iveric Bio for geographic atrophy secondary to age-related macular degeneration. The strongest claim is claim 1 because it covers the defined aptamer sequence. Claims 2 through 5 depend on that sequence and extend protection to formulations and specified clinical uses. The patent does not, on its face, claim every chemically modified, conjugated, pegylated, or sequence-related C5 aptamer.

What does US Patent 9,617,546 claim?

The patent contains four principal protection layers:

Claim	Subject matter	Commercial significance
1	Aptamer or salt containing nucleotide sequence SEQ ID NO: 4	Core sequence protection
2	Pharmaceutical composition containing the claim 1 aptamer and carrier or vehicle	Formulation and product protection
3	Treatment of C5, C5a, or C5b-9-mediated disorders	Broad therapeutic-use protection
4	Specific cardiovascular, transplant, hematologic, and surgical indications	Disease and procedure-specific use protection
5	Treatment of complement-mediated ocular tissue damage	Ocular indication protection

Claim 1 is an open-ended chemical claim only to the extent permitted by the claim language and the patent specification. The phrase "aptamer or salt thereof" does not automatically cover every derivative of the sequence. A court would likely examine whether modified nucleotides, terminal conjugates, polyethylene glycol attachment, backbone changes, and other chemical modifications preserve the claimed nucleotide sequence and fall within the patent's written description and claim-construction record.

How broad is the SEQ ID NO: 4 aptamer claim?

Claim 1 is narrow in sequence identity but potentially powerful in commercial effect. It requires the claimed aptamer to have nucleotide sequence SEQ ID NO: 4. It does not use a conventional functional genus such as "an aptamer that binds C5" or "an aptamer having at least 90% sequence identity." Competitors therefore face a materially different position depending on whether their product:

uses the exact claimed sequence;
uses a sequence variant;
includes chemical substitutions in the claimed sequence;
adds a terminal or internal conjugate;
uses a different C5-binding scaffold;
binds C5 but does not use SEQ ID NO: 4.

The claim also covers a salt of the aptamer. That language may capture pharmaceutically relevant counterion forms but generally does not convert a different nucleotide sequence into the claimed sequence.

Does claim 1 cover avacincaptad pegol?

Avacincaptad pegol is a pegylated RNA aptamer that targets complement component C5. The relationship between the marketed product and claim 1 depends on the exact sequence and chemical structure disclosed for SEQ ID NO: 4, including whether the commercial molecule contains modifications disclosed and supported in the patent.

A product can infringe a sequence claim even if it has additional chemical groups, but the additional structure must not take the product outside the claim. The literal infringement analysis would require comparison of the approved molecule's nucleotide sequence and chemical modifications with the patent disclosure. The doctrine of equivalents could expand the analysis, although prosecution-history estoppel and written-description limits may restrict that route.

What formulations are protected by US Patent 9,617,546?

Claim 2 covers a pharmaceutical composition containing:

a therapeutically effective amount of the claim 1 aptamer or salt; and
a pharmaceutically acceptable carrier or vehicle.

The claim is not limited to a specific dosage form, excipient, buffer, concentration, container, route of administration, or injection volume. It can therefore reach a wide range of compositions if they contain the claimed aptamer.

The claim does not expressly require:

intravitreal injection;
a particular concentration;
a particular dosing interval;
a particular buffer system;
a particular preservative;
a particular viscosity;
a particular pegylation pattern; or
a particular ocular formulation.

That breadth increases potential coverage of follow-on formulations but also creates validity and written-description questions if the specification does not adequately support the full range of carriers, vehicles, concentrations, and chemical variants asserted by the patent owner.

A competitor using a different C5 inhibitor, different aptamer sequence, antibody, antibody fragment, or small molecule would not ordinarily fall within claim 2 merely because the product is formulated for the same indication.

What method-of-use patents does the patent contain?

Claims 3 through 5 are method-of-use claims. They require administration of the claimed aptamer or salt to a patient in need.

Claim 3 covers treatment of disorders mediated by:

C5;
C5a; and/or
C5b-9.

Claim 4 narrows claim 3 to specified indications and complications, including:

myocardial injury associated with CABG surgery;
myocardial injury associated with balloon angioplasty;
myocardial injury associated with restenosis;
complement-mediated complications associated with CABG surgery;
percutaneous coronary intervention;
paroxysmal nocturnal hemoglobinuria;
acute transplant rejection;
hyperacute transplant rejection;
subacute transplant rejection; and
chronic transplant rejection.

Claim 5 covers complement-mediated ocular tissue damage.

The claims do not require a specific route of administration or dose. A method claim still requires the accused party to practice, induce, or contribute to the claimed treatment method. For a marketed ocular product, claim 5 is commercially more relevant than the cardiovascular and transplant indications because it maps more closely to an approved ophthalmic use.

What is the patent's relevance to geographic atrophy and Izervay?

The FDA approved Izervay, or avacincaptad pegol intravitreal solution, in 2023 for geographic atrophy secondary to age-related macular degeneration.[2] Geographic atrophy is an ocular condition associated with complement activation and is commercially aligned with claim 5's reference to complement-mediated ocular tissue damage.

The patent does not expressly name geographic atrophy in the supplied claim language. Its ocular method claim is broader at the indication level but may require proof that the treated ocular condition is complement-mediated. The regulatory label and clinical mechanism can support that characterization, but patent scope is determined by the claim language, specification, prosecution history, and applicable infringement law.

The patent's commercial value therefore depends on three questions:

whether Izervay uses the claimed SEQ ID NO: 4 aptamer;
whether the approved product's chemical modifications remain within claim 1; and
whether treatment of geographic atrophy falls within claim 5's "complement mediated ocular tissue damage" limitation.

When does US Patent 9,617,546 lose exclusivity?

The patent issued on April 11, 2017.[1] Its ordinary patent term is generally 20 years from the earliest effective nonprovisional filing date, subject to patent-term adjustment, patent-term extension, terminal disclaimers, and other USPTO-record events.[3]

The issue date does not determine expiration. A precise expiration date cannot be calculated from the claims alone. The relevant record includes:

earliest priority and nonprovisional filing dates;
patent-term adjustment;
any patent-term extension under 35 U.S.C. § 156;
terminal disclaimer information;
reexamination or post-grant proceedings;
maintenance-fee status; and
any disclaimer or expiration event recorded by the USPTO.

For commercial planning, the patent should be treated as a potentially important pre-expiration barrier, but not as the only relevant patent. Later continuation, divisional, formulation, conjugate, dosing, or indication patents may provide longer protection for the marketed product.

Does FDA regulatory exclusivity extend beyond the patent?

FDA approval exclusivity and patent exclusivity are separate. Izervay received approval through an NDA pathway rather than a biosimilar pathway. The product is not an interchangeable biologic subject to the Purple Book's biosimilar framework.

FDA regulatory protection may include:

five-year new chemical entity exclusivity if the statutory criteria are met;
three-year exclusivity for certain applications containing new clinical investigations;
orphan-drug exclusivity if the product received an orphan designation and approval for the designated use; and
pediatric exclusivity if awarded.

The existence and duration of each period must be determined from FDA approval and exclusivity records. Regulatory exclusivity does not extend the patent term, and patent expiry does not automatically eliminate FDA approval barriers.

What is the Orange Book status of the patent?

The Orange Book lists patents and exclusivity information for approved drug products. A patent is not necessarily listed merely because it covers an approved product. Listing depends on FDA submission requirements and whether the patent claims the drug substance, drug product, or an approved method of use under applicable Orange Book standards.[4]

For an oligonucleotide product such as avacincaptad pegol, the principal patent-listing questions are:

whether US 9,617,546 was submitted to FDA for listing;
whether FDA accepted the listing;
whether the listed claims cover the active ingredient, product formulation, or approved method of use;
whether a later patent has replaced or supplemented the listing; and
whether a generic applicant would face a Paragraph IV certification.

The patent claims supplied here are facially capable of supporting drug-product and method-of-use listing, but the patent text alone does not establish its current Orange Book status.

Are there Paragraph IV challenges to Izervay?

A Paragraph IV challenge can arise when an ANDA applicant certifies that an Orange Book-listed patent is invalid, unenforceable, or will not be infringed. The challenge can trigger patent litigation under the Hatch-Waxman Act and, in some circumstances, a 30-month stay of approval.

For Izervay, generic-entry analysis is more complicated than for a conventional small-molecule tablet:

avacincaptad pegol is a chemically defined oligonucleotide;
manufacturing requires sequence-specific synthesis and purification;
the product is administered by intravitreal injection;
analytical similarity and impurity control can be demanding;
formulation and container-closure requirements may create additional barriers; and
an ANDA applicant must establish the applicable pharmaceutical equivalence and bioequivalence pathway.

A Paragraph IV filing would not itself establish that the patent is weak. The relevant issues would include claim construction for SEQ ID NO: 4, written description, enablement, anticipation, obviousness, prosecution history, and whether the proposed product contains the claimed sequence or a legally equivalent structure.

No biosimilar litigation framework applies in the ordinary sense because Izervay is not a biologic reference product approved under the Public Health Service Act's 351(k) pathway.

Which companies control the commercial rights?

The commercial history of the C5 aptamer program traces to Archemix and its ARC1905 development program. Ophthotech later developed the program for retinal disease, and the company subsequently became Iveric Bio. Astellas acquired Iveric Bio in 2023.[5]

The relevant control structure is therefore:

Entity	Role
Archemix	Original C5 aptamer developer and historical patent holder or licensor
Ophthotech	Clinical developer of the retinal C5 aptamer program
Iveric Bio	Successor retinal-development company and Izervay sponsor before acquisition
Astellas	Parent company following acquisition of Iveric Bio
FDA	U.S. regulator for approval, labeling, and Orange Book records

Licensing and assignment history must be separated from inventorship. The party listed as assignee on the issued patent may not be the same entity that currently controls commercial rights. Patent assignments, exclusive licenses, security interests, and corporate acquisitions can produce different ownership and enforcement positions.

How strong is the patent estate?

US 9,617,546 has high intrinsic importance because claim 1 is directed to a defined active aptamer sequence. A composition-of-matter claim is generally stronger than a method-of-use claim when the commercial product practices the claimed structure.

Strengths

Claim 1 targets a specific therapeutic aptamer sequence.
Claims 2 through 5 create product and use fallbacks.
Claim 5 aligns with an ocular complement-mediated mechanism.
The claims do not impose a narrow dose or administration schedule.
A competitor using the identical sequence faces a direct infringement risk.

Vulnerabilities

The sequence-specific claim does not necessarily cover sequence variants.
Chemical modifications may create claim-construction disputes.
The ocular claim does not expressly name geographic atrophy.
Broad functional language in claims 3 and 5 may face enablement or written-description scrutiny if asserted beyond the examples.
Patent-term uncertainty affects the value of the remaining term.
Later product patents may be more important for actual generic-entry timing.

The patent estate is strongest against an identical-sequence product and weaker against a redesigned C5 inhibitor, a different aptamer sequence, or a non-aptamer C5 pathway inhibitor.

How does this patent compare with competing C5 inhibitor patents?

Product or platform	Modality	Principal protection issue	Relationship to US 9,617,546
Izervay, avacincaptad pegol	Pegylated RNA aptamer	Sequence, formulation, ocular use	Directly relevant if product practices SEQ ID NO: 4
Soliris, eculizumab	Monoclonal antibody	Biologic composition and manufacturing	No ordinary sequence overlap
Ultomiris, ravulizumab	Long-acting antibody	Antibody sequence, formulation, dosing	Separate antibody estate
Empaveli, pegcetacoplan	Pegylated complement inhibitor	Peptide and conjugate claims	Different molecular architecture
Zilbrysq, zilucoplan	Peptide inhibitor	Peptide composition and use	Different active ingredient
Novel C5 aptamers	Nucleic-acid ligands	Alternative sequences and modifications	Potential design-around route

The patent does not block all C5 inhibition. It protects a particular aptamer-centered product and specified uses.

What generic-entry risks exist?

The most plausible entry scenarios are:

Identical-sequence generic or follow-on product

This presents the highest infringement risk under claim 1, assuming the proposed product uses SEQ ID NO: 4 and falls within the patent's chemical scope.

Modified version of the same aptamer

Risk depends on whether the modification changes the claimed nucleotide sequence, whether the patent expressly discloses the modification, and whether the doctrine of equivalents applies.

Different C5 aptamer

A different sequence may avoid literal infringement of claim 1. It could still encounter other patents directed to C5 aptamer families, conjugates, formulations, manufacturing, or ocular indications.

Antibody or peptide C5 inhibitor

A non-aptamer C5 inhibitor would generally avoid claim 1, although it may face separate patent estates covering the active ingredient, formulation, dosing, and indication.

Competing retinal therapy

A product that treats geographic atrophy through another complement target, such as C3, may avoid the patent if it does not administer the claimed aptamer. Patent risk would then shift to other method-of-use and product patents.

What manufacturing and IP barriers affect competition?

Manufacturing is a meaningful barrier even if a competitor designs around the patent. A follow-on developer must reproduce or characterize:

the exact oligonucleotide sequence;
modified nucleotides and terminal groups;
pegylation or other conjugation;
purity and impurity profile;
aggregation and degradation behavior;
sterility and endotoxin controls;
ophthalmic formulation stability;
container-closure compatibility; and
intravitreal administration specifications.

These technical requirements do not independently establish patent infringement, but they increase development cost and regulatory execution risk. A competitor may avoid the core sequence patent while still encountering process patents, formulation patents, manufacturing know-how, trade secrets, or clinical-use patents.

Key Takeaways

US 9,617,546 is centered on a C5-binding aptamer with nucleotide sequence SEQ ID NO: 4.
Claim 1 is the principal composition-of-matter claim.
Claim 2 covers pharmaceutical compositions containing the aptamer and a pharmaceutically acceptable carrier or vehicle.
Claims 3 through 5 cover treatment of complement-mediated disorders, including ocular tissue damage.
The patent is commercially relevant to avacincaptad pegol and Izervay if the approved product practices SEQ ID NO: 4 within the claim's chemical scope.
The patent does not cover every C5 inhibitor, every C5 aptamer, or every treatment for geographic atrophy.
Exact expiration requires USPTO patent-term and assignment records.
Generic risk is highest for an identical-sequence product and lower for a redesigned aptamer, antibody, peptide, or different complement inhibitor.
FDA regulatory exclusivity, Orange Book listing, and patent term must be analyzed separately.
The later patent estate may determine actual generic-entry timing more than US 9,617,546 alone.

FAQs

Does US 9,617,546 claim geographic atrophy by name?

No. The supplied claims do not name geographic atrophy. Claim 5 covers complement-mediated ocular tissue damage, which may be relevant to geographic atrophy depending on the specification, prosecution history, and claim construction.

Is US 9,617,546 a patent on eculizumab or ravulizumab?

No. Eculizumab and ravulizumab are monoclonal antibodies with different molecular structures. US 9,617,546 claims a defined nucleic-acid aptamer sequence.

Can a competitor avoid the patent by changing one nucleotide?

Possibly, but not automatically. Literal infringement would depend on whether the changed sequence remains within the claim. The patent specification, prosecution history, and doctrine of equivalents would also affect the analysis.

Does the patent cover all pegylated C5 inhibitors?

No. It covers the claimed aptamer sequence and applicable salts. Pegylation alone does not bring a different C5 inhibitor within claim 1.

Can a generic manufacturer file an ANDA before patent expiration?

An ANDA applicant may file a Paragraph IV certification against an Orange Book-listed patent, subject to Hatch-Waxman requirements. Filing does not guarantee approval or eliminate litigation risk.

References

United States Patent and Trademark Office. (2017). U.S. Patent No. 9,617,546, Aptamer or salt thereof and pharmaceutical and therapeutic uses.
U.S. Food and Drug Administration. (2023). FDA approves first treatment for geographic atrophy, a leading cause of blindness.
United States Code. (2024). 35 U.S.C. §§ 154 and 156: Patent term and patent term extension.
U.S. Food and Drug Administration. (2023). Approved drug products with therapeutic equivalence evaluations, Orange Book.
Astellas Pharma Inc. (2023). Astellas completes acquisition of Iveric Bio.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Astellas	IZERVAY	avacincaptad pegol sodium	SOLUTION;INTRAVITREAL	217225-001	Aug 4, 2023		RX	Yes	Yes	⤷ Start Trial	⤷ Start Trial		Y		TREATMENT OF GEOGRAPHIC ATROPHY SECONDARY TO AGE-RELATED MACULAR DEGENERATION BY ADMINISTERTING AVACINCAPTAD PEGOL TO THE EYE	⤷ Start Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Patented / Exclusive Use	>Submissiondate

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Australia	2006214437	⤷ Start Trial
Brazil	PI0607002	⤷ Start Trial
Canada	2597889	⤷ Start Trial
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Details for Patent: 9,617,546

Which drugs does patent 9,617,546 protect, and when does it expire?

Summary for Patent: 9,617,546